Branded

ATLANTA — The proportion of outpatient visits for influenza-like illness was 2.8% for the week ended Feb. 16, the Centers for Disease Control and Prevention reported Friday, a strong indicator that the 2012-2013 flu season is on its way out. Nevada, New Jersey and Vermont were still reporting high ILI activity; while 13 states and New York City reported moderate activity; 11 states reported low activity; and 23 states reported minimal activity.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Bayer HealthCare Pharmaceuticals for treating tumors of the digestive system, the agency said Monday.

The FDA announced the approval of Stivarga (regorafenib) for gastrointestinal stromal tumors that could not be removed through surgery or had spread to other parts of the body and were no longer responding to treatment with Novartis' Gleevec (imatinib) or Pfizer's Sutent (sunitinib).

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for late-stage breast cancer, the agency said Friday.

The FDA announced the approval of Genentech's Kadcyla (ado-trastuzumab emtansine) for HER2-positive breast cancer that has spread to other parts of the body. HER2 is a protein involved in the growth of normal cells but found in increased amounts in some kinds of cancer cells, which contributes to cancer cell growth and survival. Genentech is the U.S. subsidiary of Swiss drug maker Roche.

ATLANTA — This year's triumvirate influenza vaccine was less effective in seniors as compared to the general population, according to the Centers for Disease Control and Prevention's "Morbidity and Mortality Weekly Report" published Friday. Overall effectiveness of the vaccine was 56%, similar to an earlier interim estimate of 62%. 

The adjusted, age-stratified vaccine effectiveness point estimates were 58% for children, 46% for adults younger than 50, 50% for men and women between the ages of 50 years and 64 years and 9% for seniors. 

WOODCLIFF LAKE, N.J. — Valeant Pharmaceuticals has bought rights to a drug used to treat skin cancer from Eisai, the companies said Thursday.

Valeant has bought the rights to Targretin (bexarotene) capsules and gel from Eisai for $65 million upfront, plus additional payments based on certain milestones. Under the deal, Eisai has transferred its regulatory approval application to Valeant, which will assume responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain rights to the drug outside the United States.

KING OF PRUSSIA, Pa. — The Food and Drug Administration has approved a new vial size for a drug made by CSL Behring to treat a bleeding disorder and an immune disorder, the company said Thursday.

BASKING RIDGE, N.J. — A division of drug maker Mylan has distributed autoinjectors of an emergency drug used for severe allergic reactions to schools nationwide.

Mylan Specialty said Wednesday that since its August 2012 launch of the EpiPen4Schools program, thousands of schools around the country had elected to participate and receive free EpiPen and EpiPen Jr (epinephrine) auto-injectors. The program was launched to help schools have improved access to epinephrine in the event that a person experiences a life-threatening allergic reaction, also known as anaphylaxis.

ARLINGTON, Va. — Lobbying groups for the retail pharmacy industry have a few suggestions for the Drug Enforcement Administration for drug take-back programs.

The National Association of Chain Drug Stores expressed support for a rule the DEA proposed in December to govern the secure disposal of controlled substances by DEA registrants - including pharmacies - and patients, as well as people acting on their behalf.